Overview

A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With

Status:
Completed
Trial end date:
2013-04-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of CNTO 1959 following a single subcutaneous (SC, under the skin) dose administered to Japanese participants with moderate to severe plaque psoriasis.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Pharmaceutical K.K.